HOLLYWOOD, FL--(Marketwire - January 15, 2009) - bioRASI, a full service, global Contract
Research Organization (CRO), announced today that Gary W. Thompson has
joined the company as Vice President of Business Development. bioRASI has
significantly expanded its worldwide operational infrastructure and is now
adding a corresponding upgrade to its business development functions. Gary
Thompson will lead these global efforts.
"We are extremely pleased to bring a person of Gary's caliber to head our
business development functions," said Dr. Boris Reznik, Chairman of
bioRASI. "Over three decades, Gary has played an integral role in shaping
the biotech and pharma industry. In every area he has proved himself a very
strong leader; likeable, knowledgeable, and well trusted by the industry.
In conjunction with the opening of several new offices around the world,
Gary will lead our efforts, providing optimal solutions to our clients'
clinical development programs."
Prior to joining bioRASI, Gary Thompson served as the Vice President of
Business Development for Bio Pharma Services as well as the Head of
Business Development for Veeda Clinical Research, one of the fastest
growing CROs in India. Previously, he has held leading business
development positions with major CROs including Bioanalytical Systems Inc.
(BASi), PPD Pharmaco Inc., and Phoenix International Life Sciences.
"I am very excited about joining the bioRASI Team and working with some of
the most dedicated, knowledgeable and accomplished professionals in the
industry," said Mr. Thompson. "bioRASI's worldwide infrastructure is a
perfect base for the optimization of Clinical Endpoints and PK clinical
programs of Biotech and Pharma industry clients. I am looking forward to
leveraging the quality, time and cost saving advantages that bioRASI offers
to help our clients achieve their business successes."
bioRASI is a Full Service Global CRO that collaborates with the leading
biotech and pharmaceutical companies in the clinical development of novel
and generic therapeutics. Specializing in ANDA and 505(b)(2) NDA programs,
bioRASI facilitates obtaining FDA approvals by delivering high quality
regulatory and clinical strategies, solutions and services, while saving
their clients critical time. bioRASI services include program management,
regulatory, clinical, data management and analysis, compliance and audit.
bioRASI leverages its access to well renowned researchers and facilities,
in the U.S., Europe and Asia, to achieve unparalleled scientific, clinical
and business results at significantly lower costs. bioRASI is headquartered
in Hollywood, FL and has regional offices, labs, and clinics across the